31 October 2023
Asclepius MedTech Ltd. provides a remote patient monitoring platform set to revolutionize pre- and post-operative surgical assessments by unleashing and unlocking the power of data.
In the wake of the COVID-19 pandemic, the NHS treatment waiting lists reached a record high of 7,4 million people, with over 410,000 patients waiting for treatment for more than a year. This challenge is seen across the rest of Europe, Canada, and the USA and it will take many years to clear this backlog.
Asclepius MedTech will revolutionize pre- and post-operative assessments for healthcare professionals (HCPs), their hospitals, and patients, with its platform analyzing combined evidence-based longitudinal multimodal data sets powered by predictive algorithms to more accurately predict patient ‘fitness for surgery’. Supporting clinicians and surgical teams, the platform will ameliorate shared decision-making so teams may better stratify patient care, reduce the risk of surgical complications, improve patient outcomes, and their recovery, and facilitate earlier discharge.
Patients for pre-operative surgery will be fitted with a CE-marked wearable biosensor, attached to the chest to capture physiological data (e.g., vital signs, activity, posture, temperature) and complete daily, app-based, clinically validated questionnaires about their health status. Data transmitted in real-time and automated with cloud analytics is presented on the hospital team’s clinical dashboard.
Professor David Jayne, clinical advisor to Asclepius Medtech Ltd., commented: “Current systems for assessing fitness for surgery are limited and frequently not accessible to the frailest patients or patients with disabilities. In comparison, the Asclepius Platform, designed for patients, provides clinicians with a richer data set that more accurately predicts the risks of surgery. It will allow clinicians to plan appropriate care pathways to minimize complications, make better treatment choices, improve efficiency, and reduce costs for healthcare providers.”
The Asclepius Platform will reduce the number of clinic visits and increase system efficiency and patient pathway optimisation, thus, improving the productivity and capacity of hospitals. Additionally, the platform has been co-designed with patients to enhance user acceptability and is shown to be less costly than Cardiopulmonary Exercise Testing (CPET).
Michael Morgan-Curran, the CEO of Asclepius MedTech Ltd., brings 15 years of experience in building, launching, and scaling up MedTech companies in the EU, MENA, and the US: “Asclepius’s innovation will not only simplify and improve pre- and post-operative surgical assessment to reduce surgical complications, improve patient outcomes, but also automate decision–making to optimize patient pathways and reduce the burden on hospitals.”
Following significant funding awards from the National Institute of Health and Care Research (NIHR) and charitable bodies for large clinical studies, the next stage for the Asclepius Platform involves upgrading the clinical dashboard, app interface with the sensor and its app to record patient-reported data to provide HCPs and surgical teams with comprehensive reports for enhanced decision-making. This will be followed by the integration of validated cloud-based predictive algorithms and additional clinical research; supported by seed investment and non-dilutive grant funding.
Asclepius MedTech Ltd. is developing an ecosystem with academic and clinical network partners, public and private hospital organizations, industry associations, national innovation accelerators, and patient advocacy groups.
The company plans a phased launch of its Platform in the UK, the EU, Canada, and the USA.
NLC is the leading European healthtech venture builder. NLC identifies top-notch early-stage healthcare inventions and brings them to market, acting as the connecting link between technology innovation and entrepreneurship in medtech, biotech and digital health. To optimize patient care and enhance its positive and sustainable impact, NLC collaborates with corporates such as Philips and healthcare and academic research institutions such as Oxford University and Mayo Clinic.
NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, 17. With its growing team of more than 80 professionals and over 110 portfolio ventures built across 11 European countries, NLC is currently expanding its impact-driven operations to the US and the Gulf region.
Discover more and join us on our journey
Asclepius MedTech Limited
Michael Morgan-Curran, CEO